TY - JOUR T1 - Estimating the burden of COVID-19 pandemic on mortality, life expectancy and lifespan inequality in England and Wales: A population-level analysis JF - medRxiv DO - 10.1101/2020.07.16.20155077 SP - 2020.07.16.20155077 AU - José Manuel Aburto AU - Ridhi Kashyap AU - Jonas Schöley AU - Colin Angus AU - John Ermisch AU - Melinda C. Mills AU - Jennifer Beam Dowd Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/09/2020.07.16.20155077.abstract N2 - Background Deaths directly linked to COVID-19 infection may be misclassified, and the pandemic may have indirectly affected other causes of death. To overcome these measurement challenges, we estimate the impact of the COVID-19 pandemic on mortality, life expectancy and lifespan inequality from week 10, when the first COVID-19 death was registered, to week 47 ending November 20, 2020 in England and Wales through an analysis of excess mortality.Methods We estimated age and sex-specific excess mortality risk and deaths above a baseline adjusted for seasonality with a systematic comparison of four different models using data from the Office for National Statistics. We additionally provide estimates of life expectancy at birth and lifespan inequality defined as the standard deviation in age at death.Results There have been 57,419 (95% Prediction Interval: 54,197, 60,752) excess deaths in the first 47 weeks of 2020, 55% of which occurred in men. Excess deaths increased sharply with age and men experienced elevated risks of death in all age groups. Life expectancy at birth dropped 0.9 and 1.2 years for females and males relative to the 2019 levels, respectively. Lifespan inequality also fell over the same period by five months for both sexes.Conclusion Quantifying excess deaths and their impact on life expectancy at birth provides a more comprehensive picture of the burden of COVID-19 on mortality. Whether mortality will return to -or even fall below-the baseline level remains to be seen as the pandemic continues to unfold and diverse interventions are put in place.What is already known on this topic COVID-19 related deaths may be misclassified thereby inaccurately estimating the full impact of the pandemic on mortality. The pandemic may also have indirect effects on other causes due to changed behaviours, as well as the social and economic consequences resulting from its management. Excess mortality, the difference between observed deaths and what would have been expected in the absence of the pandemic, is a useful metric to quantify the overall impact of the pandemic on mortality and population health. Life expectancy at birth and lifespan inequality assess the cumulative impact of the pandemic on population health.What this study adds We examine death registration data from the Office for National Statistics from 2010 to week 47 (ending on November 20) in 2020 to quantify the impact of the COVID-19 pandemic on mortality in England and Wales thus far. We estimate excess mortality risk by age and sex, and quantify the impact of excess mortality risk on excess deaths, life expectancy and lifespan inequality. During weeks 10 through 47 of 2020, elevated mortality rates resulted in 57,419 additional deaths compared with baseline mortality. Life expectancy at birth for females and males over the 47 weeks of 2020 was 82.6 and 78.7 years, with 0.9 and 1.2 years of life lost relative to the year 2019. Lifespan inequality, a measure of the spread or variation in ages at death, declined due to the increase of mortality at older ages.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJMA and RK acknowledge support from the Newton International Fellowship; JMA and JS acknowledge support from the Rockwool Foundation; JMA, RK, JBD and MM were supported by Leverhulme Trust, John Fell Fund and ERC Advanced Grant 835079.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is bases in aggregated publicly available processes data. No ethics approval is required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and scripts are available at a public repository. https://doi.org/10.5281/zenodo.3946492 ER -